New Approaches To Neuroblastoma Therapy Consortium
Clinical trials sponsored by New Approaches To Neuroblastoma Therapy Consortium, explained in plain language.
-
Immune cell boost shows promise for tough childhood cancer
Disease control OngoingThis early-phase trial tests a new combination therapy for children with neuroblastoma that has come back or not responded to treatment. It uses the child's own natural killer (NK) cells, grown in a lab, along with the drug dinutuximab, and sometimes lenalidomide, to try to contr…
Phase: PHASE1 • Sponsor: New Approaches to Neuroblastoma Therapy Consortium • Aim: Disease control
Last updated May 26, 2026 10:34 UTC
-
New hope for kids with tough cancer: drug combo trial launches
Disease control OngoingThis early-phase study tests a three-drug combination (sorafenib, cyclophosphamide, and topotecan) in children and young adults with neuroblastoma that has come back or not responded to treatment. The main goal is to find the safest dose of sorafenib when given with the other two…
Phase: PHASE1 • Sponsor: New Approaches to Neuroblastoma Therapy Consortium • Aim: Disease control
Last updated May 18, 2026 12:08 UTC
-
Scientists hunt for genetic clues in stubborn childhood cancer
Knowledge-focused OngoingThis study looks at tumor samples from children and young adults with neuroblastoma that has come back or not responded to treatment. The goal is to find specific genetic changes or immune system markers that could be targeted with future therapies. By understanding these markers…
Sponsor: New Approaches to Neuroblastoma Therapy Consortium • Aim: Knowledge-focused
Last updated May 26, 2026 10:56 UTC